n.a. (KYTH)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
First Week of November 22nd Options Trading For Kythera Biopharmaceuticals (KYTH)

First Week of November 22nd Options Trading For Kythera Biopharmaceuticals (KYTH)

Investors in Kythera Biopharmaceuticals, Inc. saw new options begin trading this week, for the November 22nd expiration.

Short Interest Increases 11.5% For KYTH

Short Interest Increases 11.5% For KYTH

The most recent short interest data has been released by the NASDAQ for the 01/31/2014 settlement date, which shows a 269,380 share increase in total short interest for Kythera Biopharmaceuticals, Inc. , to 2,613,488, an increase of 11.49% since 01/15/2014.

Use Options For a Chance To Buy KYTH at a 17% Discount

Use Options For a Chance To Buy KYTH at a 17% Discount

Looking back to 127 days ago, Kythera Biopharmaceuticals priced a 2,622,950 share secondary stock offering at $45.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday, the stock is now 5.2% higher than the offering price.

Oversold Conditions For Kythera Biopharmaceuticals (KYTH)

Oversold Conditions For Kythera Biopharmaceuticals (KYTH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of August 16th Options Trading For Kythera Biopharmaceuticals (KYTH)

First Week of August 16th Options Trading For Kythera Biopharmaceuticals (KYTH)

Investors in Kythera Biopharmaceuticals, Inc. saw new options begin trading this week, for the August 16th expiration.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These stocks could get squeezed much higher if they report positive earnings this week.

Kythera Biopharmaceuticals Becomes Oversold (KYTH)

Kythera Biopharmaceuticals Becomes Oversold (KYTH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Kythera Biopharmaceuticals At $40, Earn 15.7% Annualized Using Options

Commit To Buy Kythera Biopharmaceuticals At $40, Earn 15.7% Annualized Using Options

Investors eyeing a purchase of Kythera Biopharmaceuticals, Inc. stock, but tentative about paying the going market price of $44.33/share, might benefit from considering selling puts among the alternative strategies at their disposal.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

4 Stocks Spiking on Unusual Volume

4 Stocks Spiking on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

KYTHERA Announces Additional Positive Efficacy And Patient Satisfaction Data From ATX-101 Phase III Trials For The Reduction Of Submental Fat

KYTHERA Announces Additional Positive Efficacy And Patient Satisfaction Data From ATX-101 Phase III Trials For The Reduction Of Submental Fat

REFINE-1 and REFINE-2 Data Presented at American Society for Dermatologic Surgery (ASDS) Annual Meeting*

KYTHERA Appoints F. Michael Ball To Board Of Directors

KYTHERA Appoints F. Michael Ball To Board Of Directors

Hospira Chief Executive Officer and Former Allergan President Brings Extensive Healthcare and Aesthetics Experience

Stocks Gain as Fed Consider Reducing Stimulus

Stocks Gain as Fed Consider Reducing Stimulus

Stocks take a pause after Monday's rally. Kythera and Boston Scientific get a lift; GM says it can compete with Tesla.

KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Results For The Reduction Of Submental Fat

KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Results For The Reduction Of Submental Fat

REFINE-1 and REFINE-2 Trials Demonstrate Statistically Significant Results for Primary and Secondary Endpoints

4 Stocks Rising on Unusual Volume

4 Stocks Rising on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

RSI Alert For Kythera Biopharmaceuticals (KYTH)

RSI Alert For Kythera Biopharmaceuticals (KYTH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.